Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.4.21.4 (trypsin)
42,187 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A goat antiserum was raised by immunization with the endoglycosidase fission product of porcine estrogen receptor. Its IgG fraction was employed for ascertaining the interrelationship of receptor forms extracted from three subcellular compartments of target cells and for comparing receptors from various species. Unspecific alignments of (non-immune) IgGs giving rise to soluble complexes were avoided by removal of the receptor entity responsible with carrier-attached trypsin. Coincubation of the estradiol-tagged tryptic receptor cores and immune IgG resulted in the formation of labelled precipitates and in the release of estradiol from its binding site, in every instance tested. A minimum of three common antigenic determinants must therefore exist not only on all porcine receptor forms, but also on human, ovine, bovine, rabbit, guinea-pig and rat estrogen receptors, pointing to a high degree of phylogenetic conservation.
...
PMID:2. Mechanism of steroid action. Immunoreactivity of the core of estrogen receptors found in different subcellular compartments of target cells from a variety of mammalian species. 688 76

A clonogenic assay of long-term breast cancer cell cultures in vitro has been developed to provide a highly reproducible method with which to quantitate tumor cell killing by hormones and/or cytotoxic chemotherapeutic agents. Monolayer cultures of estrogen receptor-positive MCF-7 human breast cancer cells and of estrogen receptor-negative Evsa T cells are harvested by treatment with 0.01% trypsin:0.02% EDTA in Hanks' balanced salt solution. Cell suspensions are treated with drug or hormone in serum-free medium for 1 hr at 37 degrees; treated cells are washed, plated, and cultured for approximately 14 days; and colonies consisting of greater than or equal to 30 cells are counted. Compared to estrogen receptor-positive cells, estrogen receptor-negative cells were 2-fold more sensitive to melphalan but were conversely 1.9-fold more resistant to Adriamycin; these differences were statistically significant (p less than 0.001). Thus, response to cytotoxic chemotherapeutic agents appeared to be independent of estrogen receptor status. For cells treated with diethylstilbestrol, the dose of drug or hormone reducing the surviving cell fraction to 1/e (DO) for estrogen receptor-positive cells was 2.27 nmol/ml, and that for estrogen receptor-negative cells was 2.80 nmol/ml; this difference was not statistically significant. However, with tamoxifen therapy, the DO for estrogen receptor-positive cells was 0.601 nmol/ml, and that for estrogen receptor-negative cells was 3.64 nmol/ml; this 6-fold greater degree of resistance to tamoxifen of estrogen receptor-negative cells was highly significant (p less than 0.001). Treatment of cells for 24 hr with 17 beta-estradiol stimulated proliferation not only of estrogen receptor-positive cells but also of estrogen receptor-negative cells. However, estradiol at concentrations up to 200 microM had no apparent cytocidal activity, as measured by the clonogenic assay. Furthermore, treatment of MCF-7 cells simultaneously with estradiol and either diethylstilbestrol or tamoxifen failed to reverse the cytocidal activity of those two agents. These findings suggest that, in the clonogenic assay described herein, diethylstilbestrol and tamoxifen may kill human breast cancer cells by an independent mechanism of action and that the cytocidal activity of diethylstilbestrol and the proliferative effect of 17 beta-estradiol appear to be independent of estrogen receptor status.
...
PMID:Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro. 713 16

To understand how estradiol-17 beta (E2) influences MtTW15 rat pituitary tumor function, we have evaluated the cytosolic E2 binding properties of tumors derived from control and steroid treated host animals. Specific E2 binding (approximately 3 pmoles/g tumor) was observed in all groups and was steroid responsive. The E2 binding macromolecule migrated to 7S following sucrose density gradient sedimentation and was specific for estrogenic steroids. Saturation analysis of E2 binding revealed a high affinity interaction (Kd = 5.5 +/- 0.5 x 10(-10) M). Furthermore, E2 binding was temperature-sensitive and degraded by trypsin. Thus, the MtTW15 tumor contains an estrogen receptor. Accordingly, the effects of 4 antiestrogenic drugs on tumor estrogen-receptor levels, tumor growth and hormone production were evaluated. In general, these drugs reduced cytosolic estrogen receptor levels, promoted tumor growth and increased tumor growth-hormone production. It is suggested that these compounds can exert both estrogen agonist and antagonist properties in MtTW15 tumors.
...
PMID:Estrogen receptor-like macromolecule in MtTW15 rat pituitary tumors: effects of antiestrogens. 728 85

Estrogen and progesterone receptors from chick oviduct were compared with respect to their chromatographic behaviour on DEAE-cellulose and their DNA-binding ability to test the general validity of the subunit model from O'Malley and coworkers. Both hormone-receptor complexes can be separated on DEAE-cellulose into 2 components A and B. The 2 progesterone-receptor components appear to occur in equimolar amounts, whereas in the case of the estrogen receptor the amount of component A is always significantly larger. After trypsin treatment the estrogen component B disappears. The remaining A is a receptor fragment with reduced molecular weight. This and other data indicate that the estrogen component B represents an aggregated form of the estrogen receptor and not a receptor subunit. The trypsinated progesterone-receptor fragments, however, are still separable into 2 components, even though also reduced in molecular weight. Our DNA-binding data of the progesterone-receptor components are almost consistent with earlier data from O'Malley and coworkers, even though we find some DNA-binding ability also for component B. Both estrogen-receptor components exhibit affinity for DNA and significantly more than 50% (up to 80%) of the total estrogen-receptor complex are able to bind to DNA. Furthermore we could show that the estrogen-receptor from chick oviduct can be transformed from a DNA-non-binding to a DNA-binding form, similar to other steroid-hormone receptors. This is not compatible with pre-existing receptor subunits in equimolar amounts, one with and the other without affinity for DNA.
...
PMID:The general validity of the subunit model of the progesterone receptor from chick oviduct appears questionable. Comparison of progesterone and estrogen receptor. 739 2

Partial purification and characterization of a cytoplasmic component of cow uterus, which specifically binds with native "4S" estrogen receptor (ER) to give "8S" ER was carried out. The component was designated as "8S" ER-forming factor [("8S"ER)-FF]. ("8S"ER)-FF did not bind estradiol by itself. The Stokes radius of ("8S"ER)-FF was estimated to be approximately 51 A. ("8S"ER)-FF sedimented at around 6.9S in sucrose gradient centrifugation under hypotonic conditions. The molecular weight and frictional ratio of ("8S"ER)-FF were calculated to be 145,000 and 1.47, respectively. ("8S"ER)-FF was degraded by trypsin treatment, but was not affected by DNase or RNase. The Stokes radius of "8S" ER was estimated to be approximately 68 A. The molecular weight and frictional ratio of "8S" ER were calculated to be 225,000 and 1.69, respectively. "8S" ER was estimated to be a 1 : 1 complex between native "4S" ER and ("8S"ER)-FF. It was estimated that in the cow uterine cytosol, there was at least a 3-fold molar excess of ("8S"ER)-FF over the amount of "4S" ER. ("8S" ER)-FF inhibited both the Ca2+-dependent and -independent modifications of native "4S" ER by the cytoplasmic protease.
...
PMID:Estrogen receptor of cow uterus. II. Characterization of a cytoplasmic factor which binds with native "4S" estrogen receptor to give "8S" estrogen receptor. 745 23

Cytosol from MTW9 rat mammary tumor contains a high molecular weight inhibitor of estrogen receptor binding to DNA. RNase treatment of crude preparations destroys inhibitory activity, whereas DNase or trypsin treatment are without affect, suggesting that some RNA molecule might be involved; in addition, RNA extracted from tumor cytosol was an effective inhibitor of estrogen receptor binding to DNA. A number of synthetic and natural RNA species were analyzed for inhibitory activity; a definite specificity was observed, with poly(G) > poly(U) > poly(A) or poly(C).
...
PMID:RNA inhibits estrogen receptor binding to DNA. 745 96

The structure of the ca. 250 amino acid hormone binding domain of the human estrogen receptor (hER-LBD), expressed in E. coli and purified as a complex with estradiol, has been probed by selective proteolysis, with analysis of the protein fragments both by classical methods (SDS-PAGE and Edman N-terminal sequencing) and by mass spectrometry (HPLC-coupled electrospray ionization mass spectrometry (LC/ESI-MS)). Rapid cleavage by several proteases (trypsin, chymotrypsin, thermolysin, and Asp-N endoproteinase) is observed within a localized region (residues 297-303) at the N-terminus. In contrast, proteolytic scission at the C-terminus is less localized and more progressive; initial cuts by trypsin, chymotrypsin, thermolysin, V8, and Asp-N proteinases are observed to occur in the region 553-571, followed by further cleavage with thermolysin (548) and trypsin (548, 531, and 529). Thus, N304 and K529 define the protease-resistant N- and C-termini of a core structure for this domain that appears to contain the elements sufficient for ligand binding. The remaining segment of this domain (530-553), which is known to embody elements essential for ligand-modulated transcription activation (AF-2), is likely a surface-exposed region that, through these studies, is shown to be accessible to proteases. Only a single region within the 26 kDa ligand-binding core (N304-K529) has been identified as being readily accessible to proteases; rapid proteolysis using the proteases trypsin, chymotrypsin, and thermolysin, is localized to residues 465-468, with cleavage occurring at residues K467, L466, and both T465 and S468, respectively. The flexibility implied by the cuts in this internal 465-468 region suggest that the hER-LBD may actually consist of two subdomains. These proteolysis studies provide a substantially refined view of the conformational nature of the human estrogen receptor ligand binding domain.
...
PMID:Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. 754 10

Experiments were carried out to determine the degree of solvent and reagent accessibility of the cysteines in the ligand-binding domain of the human estrogen receptor (hER LBD). The cysteine residues were alkylated when human ER LBD was present in its ligand (estradiol)-bound conformation. Direct electrospray ionization mass spectrometry (ESMS) as well as liquid chromatography coupled with ESMS, and matrix-assisted laser ionization desorption time-of-flight mass spectrometry were used to determine the location and the yield of the derivatized residues after proteolysis with trypsin. We observed that the cysteine 447 was protected against alkylation under these conditions, whereas cysteines 381, 417, and 530 were fully derivatized.
...
PMID:Carboxymethylation of the human estrogen receptor ligand-binding domain-estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid. 877 99

The estrogen receptor (ER) is a ligand-dependent transcription factor that regulates the expression of estrogen-responsive genes. ER-mediated transcriptional changes are brought about by interaction of the ER with the estrogen response element (ERE). In this study, we examined the interaction of the Xenopus laevis ER DNA binding domain (DBD) and the intact ER with the X. laevis vitellogenin A2 ERE and the human pS2 ERE. Using gel mobility shift, DNase I footprinting, and methylation interference assays, we demonstrated that the DBD bound only as a dimer to the A2 ERE. However, the DBD bound as a monomer to the consensus pS2 ERE half site at lower DBD concentrations and then as a homodimer to the consensus and imperfect pS2 ERE half site at higher DBD concentrations. Antibody supershift experiments carried out with partially purified, yeast-expressed full-length ER demonstrated that three ER-specific antibodies interacted differentially with A2 and pS2 ERE-bound ER, indicating that receptor epitopes were differentially exposed. Furthermore, partial digestion of the A2 and pS2 ERE-bound ER with chymotrypsin or trypsin produced distinct protease cleavage patterns. Taken together, these data provide evidence that differential interaction of the DBD with the A2 and pS2 EREs brings about global changes in ER conformation. The conformational changes in ER induced by individual ERE sequences could lead to association of the receptor with different transcription factors and assist in the differential modulation of estrogen-responsive genes in target cells.
...
PMID:Estrogen response elements function as allosteric modulators of estrogen receptor conformation. 952 64

Genistein, a natural flavone compound, has been proposed to be responsible for the lower rate of breast cancer in Asian women. The cellular mechanisms of genistein's inhibition of breast cancer progression are largely unknown. In a previous study our laboratory has presented evidence that genistein inhibits cell proliferation of breast carcinoma cells, an inhibition which is associated with a specific G2/M arrest, induction of p21WAF/CIP1 expression and apoptosis. In the present study, we present experimental evidence that illustrates that the actions of genistein are not limited to anti-proliferation: we show that genistein can inhibit both constitutive as well as epidermal growth factor (EGF)-stimulated invasion in estrogen receptor (ER)-negative human breast carcinoma lines, MDA-MB-231 and MDA-MB-468. This inhibition is characterized by the down regulation of MMP-9 (92 kDa type IV collagenase) and up regulation of TIMP-1 (tissue inhibitor of metalloproteinases) and the trypsin inhibitors: protease nexin-II (PN-II) and alpha 1-antitrypsin (alpha 1-AT). The in vivo actions of genistein may therefore extend beyond those traditionally implicated in chemoprevention, e.g., antiproliferation; genistein may act in vivo by blocking additional stages of breast cancer progression such as those stages resulting in invasion and metastasis.
...
PMID:Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. 967 52


<< Previous 1 2 3 4 5 6 7 Next >>

---